The recurrence patterns of stages I, II and III neuroblastoma: Experience with 77 relapsing patients

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 183-187

  Berthold, F ^a   Hero, B ^a   Breu, H ^b   Christiamen, H ^c   Erttmann, R ^d   Gnekow, A ^e   Herrmann, F ^f   Klingebiel, T ^g   Lampert, F ^c   Muller Weihrich St ^h   Weinel, P ⁱ  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Dortmund Hospital   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e Augsburg Community Hospital   (Germany)

^f St Augustin Community Hospital   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

N myc; Neuroblastoma; Recurrence; Risk factor; Screening; Transition

Indexed keywords

ARTICLE; CANCER RECURRENCE; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; SURVIVAL;

EID: 13344285359     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010547     Document Type: Article

References (22)

1. Nitschke R, Smith AI, Altshuler G et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 1991; 7: 1181-8.
2. de Bernardi B, Conte M, Mancini A et al. Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group of Neuroblastoma. J Clin Oncol 1995; 13: 884-93.
3. Carlsen N. Neuroblastomas in Denmark 1943-80. Epidemiological and clinical studies. Acta Paediatr 1994; 403 (Suppl): 1-26.
4. Philip T, Zucker JM, Bernard JL et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 1991; 6:1037-44.
5. Pearson AD, Craft AW, Pinkerton CR et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992; 10: 1654-9.
6. Matthay KK, Seeger RC, Reynolds CP et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the children's cancer group. J Clin Oncol 1994; 11: 2382-9.
7. Pritchard J. 'Megatherapy' for advanced neuroblastoma-rationale and role. Eur J Cancer 1995; 2: 134-6.
8. Brodeur GM. Clinical significance of genetic rearrangements in human neuroblastomas. Clin Chem 1989; 7: 38-42.
9. Schwab M. Oncogene amplification in neoplastic development and progression of human cancer. Crit Rev Oncogen 1990; 2: 35-51.
10. Look T, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 4: 581-91.
11. Bourhis J, De Vathaire F, Wilson GD et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991; 51: 33-6.
12. Christiansen H, Delattre O, Fuchs S et al. Lampert: Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: Results of the German neuroblastoma study group. Prog Clin Biol Res 1994; 385: 19-25.
13. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediat Oncol 1995; 24: 215-21.
14. Sansone R, Strigini P, Badiali M et al. Age-dependent prognostic significance of N-myc amplification in neuroblastoma. The Italian Experience. Cancer Genet Cytogenet 1991; 54: 253-7.
15. Combaret V, Lasset C, Frappaz D et al. Evaluation of CD44 prognostic value in neuroblastoma: Comparison with the other prognostic factors. Eur J Cancer 1995; 31: 545-8.
16. Christiansen H, Sahin K, Berthold F et al. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 1995; 31: 541-4.
17. Kaatsch P, Haaf HG, Michaelis J. Childhood malignancies in Germany - methods and results of a nationwide registry. Eur J Cancer 1995; 31A: 993-9.
18. Evans AE. Staging and treatment of neuroblastoma. Cancer 1980; 45: 1799-802.
19. Berthold F, Kassenböhmer R, Zieschang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediat Hematol/Oncol 1994; 16: 107-15.
20. Berthold F, Burdach S, Kremens B et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Pediatric Oncology Society) experience. Klin Pädiatr 1990; 202: 262-9.
21. Berthold F, Hunneman DH, Käser H et al. Neuroblastoma screening: Arguments from retrospective analysis of three german neuroblastoma trials. Am J Pediat Hematol/Oncol 1991; 13: 8-13.
22. Cavenee WK. Los of heterozygosity in stages of malignancy. Clin Chem 1989; 35(7): B48-B52.